Beijing Luzhu Biotechnology Co (HKSE:02480) Change In Working Capital : HK$0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Change In Working Capital?

Beijing Luzhu Biotechnology Co's change in working capital for the quarter that ended in Jun. 2023 was HK$0.00 Mil.

Beijing Luzhu Biotechnology Co's change in working capital for the fiscal year that ended in Dec. 2022 was HK$-2.03 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Beijing Luzhu Biotechnology Co Change In Working Capital Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Change In Working Capital Chart

Beijing Luzhu Biotechnology Co Annual Data

Trend

Dec21

Dec22

Dec23

Change In Working Capital

2.43

-2.03

Beijing Luzhu Biotechnology Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Working Capital	-	-	-	-	-

Beijing Luzhu Biotechnology Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Beijing Luzhu Biotechnology Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Executives

Ma Jianan	2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo	2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
China Construction Bank Corporation	2201 Interest of corporation controlled by you
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Peng Ling	2201 Interest of corporation controlled by you
Zhang Yanping	2202 Interest of your spouse
Kong Jian	2101 Beneficial owner
Ma Biao	2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines